Charles Koo, MD
Clinical Cardiac Electrophysiology · Eatontown, NJNPI 1396782595
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (56.6%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 63.9% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2022 at $11,525 and has fallen 75.7% since, to $2,805 in 2025.
Across 163 payments — averaging $174.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$18K
- Biosense Webster, Inc.$8K
- Abbott$1K
- Boston Scientific$680
- Novartis$144
- SK Life Science, Inc.$125
- plus $382 from 11 others
Across 22 payments — averaging $1954.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$38K
- Medtronic$4K
- Boston Scientific$612
What the payments were for
- Consulting fees$16,15057%
- Travel & lodging$6,55823%
- Food & beverage$5,81320%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 84 | $18,220 |
| Biosense Webster, Inc. | 5 | $7,891 |
| Abbott | 15 | $1,079 |
| Boston Scientific | 25 | $680 |
| Novartis | 8 | $144 |
| SK Life Science, Inc. | 1 | $125 |
| Johnson & Johnson | 7 | $102 |
| Sanofi-aventis U.S. LLC | 5 | $76 |
| E.r. Squibb & Sons, L.L.C. | 5 | $74 |
| Novo Nordisk | 1 | $25 |
| Heartflow, Inc. | 1 | $23 |
| Kerecis Limited | 1 | $19 |
| Amgen | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $15 |
| Amarin Pharma, Inc. | 1 | $15 |
| AstraZeneca | 1 | $14 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Carto 3$7,650
- Arctic Front$1,235
- DIAMONDTEMP BIDIRECTIONAL ABLATION CATHETER$779
- CARDIOBLATE CRYOFLEX$743
- AVEIR$624
- ARCTIC FRONT ADVANCE$569
- AURORA EV-ICD MRI SURESCAN$251
- Micra$231
- WATCHMAN FLX$163
- Xience Sierra Coronary Stent System$140
- XCOPRI$125
- Carto 3 System$125
- Advisor Catheter$116
- NA$101
- Watchman$100
How this compares
$28,521 in reported general payments places this provider in the 70th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.
See all clinical cardiac electrophysiology providers in New Jersey →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 501 | $578,728 |
| XareltoRivaroxaban | 372 | $435,006 |
| EntrestoSacubitril/Valsartan | 171 | $195,848 |
| MultaqDronedarone Hcl | 24 | $35,010 |
| Dofetilide | 142 | $26,204 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 46 | $13,490 |
| PradaxaDabigatran Etexilate Mesylate | 32 | $12,165 |
| FarxigaDapagliflozin Propanediol | 12 | $8,518 |
| Flecainide Acetate | 115 | $7,590 |
| Metoprolol Succinate | 387 | $7,284 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 118 | $4,631 |
| SotalolSotalol Hcl | 122 | $3,165 |
| Atorvastatin Calcium | 236 | $2,918 |
| Ezetimibe | 82 | $2,686 |
| Valsartan | 69 | $2,249 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $102 | $435,006372 claims |
| NovartisEntresto | $144 | $195,848171 claims |
| Sanofi-aventis U.S. LLCMultaq | $76 | $35,01024 claims |
| AstraZenecaFarxiga | $14 | $8,51812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 102 clinical cardiac electrophysiology providers in New Jersey.
Other clinical cardiac electrophysiology in Eatontown
- Mariam WassefEatontown$27K
- Eran ZacksEatontown$27K
- Mark MascarenhasEatontown$17K
- Benjamin D SouzaCherry Hill$741K
- Suneet MittalParamus$722K
- George MarkHaddon Heights$312K
- Raffaele CorbisieroBrowns Mills$135K
- Emad AzizNewark$112K
- Marc RoelkeWest Orange$110K
- Arjun TheerthamParlin$102K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.